By 
There are two versions of this question. There is what the drug is licensed for, which is written down and precise. And there is what you can get, which depends on your insurer, your prescriber and how much you are willing to pay. They are not the same question, and conflating them is how people end up buying from places they should not.
Semaglutide for weight is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with a weight-related condition. There is a separate cardiovascular indication at BMI 27 or above for people with established heart disease, and a newer indication for a specific liver condition. It is contraindicated outright, not “use with caution”, if you or a close relative have had medullary thyroid carcinoma or MEN 2. If nobody asked you about thyroid cancer in your family, you were not properly assessed.
| Weight indication | BMI 30 or above |
|---|---|
| Weight indication with a comorbidity | BMI 27 to 29.9 plus a weight-related condition |
| Cardiovascular indication | BMI 27 or above with established cardiovascular disease |
| Newer indication | A specific liver condition |
| Absolute contraindication | Personal or family history of medullary thyroid carcinoma |
| Absolute contraindication | Multiple endocrine neoplasia type 2 (MEN 2) |
| The question you should have been asked | Whether anyone in your family has had thyroid cancer |
| Where BMI misleads in men | Muscular men can exceed a BMI threshold without excess fat; central fat can matter at a lower BMI |
What BMI do you need to qualify for a GLP-1?
For weight reduction in adults, the licensed criteria are:
- BMI of 30 or above: obesity, on its own, qualifies.
- BMI of 27 to 29.9: overweight, qualifies only with at least one weight-related condition. High blood pressure, type 2 diabetes, high cholesterol and obstructive sleep apnea are the usual ones.
That second criterion is where a great many men sit, and it is worth knowing that the qualifying condition may be one you have not been diagnosed with. Sleep apnea is undiagnosed in roughly 80% of moderate-to-severe cases, and it is precisely the kind of condition that both qualifies you and independently deserves treating.
What else are these drugs approved for?
The label has expanded, and most people discussing these drugs have not noticed. Semaglutide is now also indicated:
- To reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, here the threshold is a BMI of 27 or above.
- For non-cirrhotic MASH, metabolic dysfunction-associated steatohepatitis, with moderate to advanced liver fibrosis.
- In adolescents aged 12 and over with obesity, defined by BMI at or above the 95th percentile for age and sex.
The cardiovascular indication in particular changes the conversation. It reframes the drug from a weight-loss product to a cardiovascular one that also reduces weight, and it means the argument for treatment does not rest solely on the number on the scale.
Who should never take a GLP-1?
Two things rule the drug out entirely:
- A personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia syndrome type 2. This follows from the boxed warning about thyroid C-cell tumours in rodents. It is a contraindication, not a caution.
- Known hypersensitivity to semaglutide or any of its excipients.
Beyond those, a history of pancreatitis, active gallbladder disease, severe gastrointestinal disease including gastroparesis, and pregnancy or planning pregnancy are all reasons for a genuine conversation rather than a form. The side-effects article covers why.
Is BMI a fair measure for men?
BMI is a crude instrument and it is crude in a specifically male way: it does not distinguish muscle from fat. A heavily muscled man can cross 30 without carrying meaningful excess adiposity. That is the well-known failure, and it is genuinely a failure.
The less-discussed failure runs the other way, and it matters more. A man can sit at a BMI of 26 or 27 while carrying substantial visceral fat: the metabolically active fat around the organs, and be at real cardiometabolic risk while failing the threshold on paper.
Waist circumference captures this better than BMI does, which is part of why the head-to-head trial reported it as a primary outcome alongside weight. If your BMI is borderline, a waist measurement and a look at blood pressure, lipids and fasting glucose will tell you more about whether you need treatment than the BMI alone.
What should a proper assessment include?
A legitimate prescribing assessment covers, at minimum:
- Your height, weight and a genuine BMI calculation
- Whether you have a weight-related condition, if your BMI is in the 27–29.9 band
- Personal or family history of thyroid cancer, specifically medullary thyroid carcinoma or MEN 2
- Any history of pancreatitis or gallbladder disease
- Your other medications, particularly insulin or sulfonylureas
- Whether you are planning a pregnancy with a partner, and contraception where relevant
- What happens when treatment ends
If a service prescribed for you without asking about thyroid cancer in your family, that is not a paperwork oversight. It is the one question the boxed warning exists to prompt.
The last item on that list is the one almost never covered, and it is the one most likely to determine whether the whole exercise was worth it. Two-thirds of the loss returns within a year of stopping.
What if you do not qualify?
Not qualifying is not the same as having no options, and it is a considerably better position than qualifying and being sold the drug by someone who did not ask the questions above.
Diet and exercise have real trial evidence, work on the same underlying problem, and are the thing that has to carry the load after the drug stops regardless. Screening from 35 for prediabetes catches the window where the condition is most reversible. And if your sleep is broken, treating that changes appetite, energy and blood pressure at once.
What is not a reasonable alternative is buying semaglutide from somewhere that did not ask whether you qualify. The compounded market exists precisely because the legitimate route says no to some people, and the reasons it says no do not stop applying.
Common questions about qualifying for a GLP-1
What BMI do you need for Wegovy or Zepbound?
A BMI of 30 or above qualifies on weight alone. A BMI of 27 to 29.9 qualifies if you also have a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. There is a separate cardiovascular indication at BMI 27 or above for people with established heart disease.
Who should not take a GLP-1?
Anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia type 2, should not take these drugs at all. This is an absolute contraindication rather than a caution. Pregnancy is also a contraindication, and a history of pancreatitis warrants a careful conversation.
Can you get a GLP-1 without a high BMI?
Through a legitimate prescriber, not usually, because the licensed indications are defined by BMI thresholds. Services that prescribe without meeting them are working outside the label. The more useful question for a man just under the threshold is whether waist circumference and metabolic markers tell a different story than BMI does.
Is BMI accurate for men?
It is a population screening tool, not an individual diagnosis, and it misclassifies in both directions. A muscular man can cross a BMI threshold without excess body fat, and a man carrying significant visceral fat can sit under it while being metabolically unwell. Waist circumference and blood markers add what BMI misses.
What should a proper assessment include?
Height, weight and BMI; waist circumference; blood pressure; a metabolic panel including HbA1c and lipids; a medication review; and direct questions about personal and family history of thyroid cancer, MEN 2, pancreatitis and gallbladder disease. A form that asks only your weight is not an assessment.
Sources
- US Food and Drug Administration. Wegovy (semaglutide) Highlights of Prescribing Information. FDA label (PDF)
- American College of Cardiology. SURMOUNT-5, 2025. ACC
- US Preventive Services Task Force. A and B Recommendations. USPSTF
This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.